Multidisciplinary advances in skeletal physiology offer a new paradigm for the effects of growth hormone (GH) and other agents on bone and osteoporosis. The still-evolving Utah paradigm of skeletal physiology supplements earlier ideas with later discovered roles of the skeleton’s tissue-level ‘nephron equivalents’ and muscle strength in skeletal development, physiology and disorders. This article summarizes how these factors could influence the effects of GH on bone strength and bone ‘mass’, and the use of GH in the treatment of osteoporoses. Although the cellular and molecular biological mechanisms involved remain obscure, the associated cascades of cellular, genetic and biochemical processes and molecules should offer many opportunities to find or design agents that have medically useful effects on bone and muscle without giving rise to unwanted side-effects.

Keywords:
Osteoblasts, Bone, Biomechanics, Modelling, Remodelling, Pharmacology, Endocrinology
1.
Andreassen TT, Jorgensen PH, Flyvbjerg A, Orskov H, Oxlund H: Growth hormone stimulates bone formation and strength of cortical bone in aged rats. J Bone Miner Res 1995;10:1057–1067.
2.
Bouillon R: Growth hormone and bone. Horm Res 1991;36(suppl):49–55.
3.
Halloran BP, Bickle DD, Harris J, Autry CO, Currier PA, Tanner S, Patterson-Buckendahl P, Morey-Holton E: Skeletal unloading induces selective resistance to the anabolic actions of growth hormone on bone. J Bone Miner Res 1995;10:1168–1176.
4.
Polanyi M: Life’s irreducible structure. Science 1968;160:1308–1312.
5.
Prakasam G, Yeh JK, Chen M-M, Castro-Magna M, Liang CT, Aloia JF: Effects of growth hormone and testosterone on cortical bone formation and bone density in aged orchiectomized rats. Bone 1999;24:491–497.
6.
Raisz LG: Hormonal regulation of bone growth and remodelling. Ciba Found Symp 1988;136:226–238.
7.
Schiltz PM, Ohta T, Glass D, Mohan S, Baylink DJ: Growth hormone stimulates cortical bone formation in immature hypophysectomized rats. Endocr Res 1992;18:19–30.
8.
Verhaeghe J, Van Bree R, Van Herck E, Thomas H, Skottner A, Dequeker J, Mosekilde L, Einhorn TA, Bouillon R: Effects of recombinant human growth hormone and insulin-like growth factor-I, with or without 17β-estradiol, on bone and mineral homeostasis of aged ovariectomized rats. J Bone Miner Res 1996;11:1723–1735.
9.
Wilson JD, Foster DW (eds): William’s Textbook of Endocrinology, ed 8. Philadelphia, WB Saunders, 1992.
10.
Riggs BL, Melton LJ III (eds): Osteoporosis: Etiology, Diagnosis and Treatment, ed 2. Hagerstown, Lippincott-Raven, 1995.
11.
McLean FC, Urist MR (eds): Bone, ed 2. Chicago, University of Chicago Press, 1961.
12.
Frost HM: Spinal tissue vital biomechanics for clinicians; in Takahashi HE (ed): Spinal Disorders in Growth and Aging. Tokyo, Springer Verlag, 1995, pp 95–126.
13.
Bilezikian JP, Raisz LG, Rodan GA (eds): Principles of Bone Biology. Orlando, Academic Press, 1996.
14.
Favus MJ (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, ed 3. New York, Lippincott-Raven Press, 1996.
15.
Frost HM: Skeletal structural adaptations to mechanical usage (SATMU): 2. Redefining Wolff’s law: The remodeling problem. Anat Rec 1990;226:414–422.
16.
Schiessl H, Willnecker J: New insights about the relationship between bone strength and muscle strength; in Schönau E, Matkovic V (eds): Paediatric Osteology. Prevention of Osteoporosis – a Paediatric Task? Amsterdam, Excerpta Medica, 1998, pp 33–39.
17.
Schiessl H, Willnecker J: Muscle cross sectional area and bone cross sectional area in the lower leg measured with peripheral computed tomography; in Lyritis GP (ed): Musculoskeletal Interactions, vol II. Athens, Hylonome Editions, 1999, pp 47–52.
18.
Frost HM: Wolff’s Law and bone’s structural adaptations to mechanical usage: An overview for clinicians. Angle Orthod 1994;64:175–188.
19.
Frost HM (ed): Introduction To A New Skeletal Physiology, vols I and II. Pueblo, Colorado, The Pajaro Group, 1995.
20.
Frost HM: Bone development during childhood: Insights from a new paradigms; in Schönau E (ed): Paediatric Osteology. New Trends and Developments in Diagnostics and Therapy. Amsterdam, Elsevier Science, 1996, pp 3–39.
21.
Jee WSS, Frost HM: Skeletal adaptations during growth. Triangle (Sandoz) 1992;31:77–88.
22.
Takahashi HE (ed): Spinal Disorders in Growth and Aging. Tokyo, Springer-Verlag, 1995.
23.
Frost HM: Osteoporoses: Their nature, and therapeutic targets (insights from a new paradigm); in Whitfield JF, Morely P (eds): Anabolic Treatments for Osteoporosis. Boca Raton, CRC Press, 1997, pp 1–29.
24.
Frost HM: Osteoporoses: New Concepts and Some Implications for Future Diagnosis, Treatment and Research (based on insights from the Utah paradigm). Berlin, Ernst Schering Research Foundation AG, 1998, pp 7–57.
25.
Jee WSS: The skeletal tissues; in Weiss L (ed): Cell and Tissue Biology. A Textbook of Histology. Baltimore, Urban and Schwartzenberg, 1989, pp 211–259.
26.
Wronski TJ, Morey ER: Effect of spaceflight on periosteal bone formation in rats. Am J Physiol 1993;13:305–309.
27.
Jee WSS, Zhou H, Yao W, Cui L, Ma YF: The interaction of mechanical loading and bone anabolic agents. Proceedings of the Third International Congress on Osteoporosis, 31 March–3 April, 1999. Xi’an, P.R. China. Beijing, Chinese Osteoporosis Society, 1999, pp 78–83.
28.
Jee WSS: The interactions of muscles and skeletal tissue; in Lyritis GP (ed): Musculoskeletal Interactions, vol II. Athens, Hylonome Editions, 1999, pp 35–46.
29.
Kannus P, Sievanen H, Vuori L: Physical loading, exercise and bone. Bone 1996;18(suppl 1):1–3.
30.
Frost HM: Strain and other mechanical influences on bone strength and maintenance. Curr Opin Orthopaed 1997;8:60–70.
31.
Kiratli BJ: Immobilization osteopenia; in Marcus R, Feldman D, Kelsey J (eds): Osteoporosis. San Diego, Academic Press, 1996, pp 833–850.
32.
Frost HM: Bone ‘mass’ and the ‘mechanostat’. A proposal. Anat Rec 1987;219:1–9.
33.
Frost HM: Could some biomechanical effects of growth hormone help to explain its effects on bone formation and resorption? Bone 1998;23:395–398.
34.
Burr DB, Martin RB: Mechanisms of bone adaptation to the mechanical environment. Triangle (Sandoz) 1992;31:59–76.
35.
Jee WSS: The anabolic agents and the mechanostat; in Lyritis GP (ed): Advances in Osteoporosis, vol I. Athens, Hylonome Editions, 1998, pp 37–52.
36.
Frost HM: Skeletal structural adaptations to mechanical usage (SATMU): 1. Redefining Wolff’s law: The bone modeling problem. Anat Rec 1990;226:403–413.
37.
Frost HM: ‘Osteoporoses’: A rationale for further definitions? Calcif Tissue Int 1998;62:89–94.
38.
Burr DB, Milgrom C, Fyrhie D, Forwood M, Nyska M, Finestone A, Saiag E, Simkin A: In vivo measurement of human tibial strains during vigorous activity. Bone 1995;18:405–410.
39.
Martin RB, Burr DB, Sharkey NA (eds): Skeletal Tissue Mechanics. New York, Springer-Verlag, 1998.
40.
Frost HM: On rho, a marrow mediator and estrogen: Their roles in bone strength and ‘mass’ in human females, osteopenias and osteoporoses (insights from a new paradigm). J Bone Miner Metab 1998;16:113–123.
41.
Wronski TJ, Morey ER: Skeletal abnormalities in rats induced by weightlessness. Metab Bone Dis Relat Res 1992;4:69–76.
42.
Frost HM: Skeletal structural adaptations to mechanical usage (SATMU): 4. Mechanical influences on fibrous tissues. Anat Rec 1990;226:433–439.
43.
Chen M-M, Yeh JK, Aloia JF: Skeletal alterations in hypophysectomized rats: II. A histomorphometric study on tibial cortical bone. Anat Rec 1995;241:513–518.
44.
Yeh JK, Chen MM, Aloia JF: Skeletal alterations in hypophysectomized rats: I. A histomorphometric study in tibial cancellous bone. Anat Rec 1995;241:505–512.
45.
Burr DB: Muscle strength, bone mass, and age-related bone loss. J Bone Min Res 1997;12:1547–1551.
46.
Carlson CS, Weckel BM, Loeser RF, Lee HL, Gardin JF, Jerome CP: Long-term anabolic steroid treatment increases body weight and bone volume but not osteoarthritis severity in monkeys. Orth Res Soc 1996;222 (abstract).
47.
Ferretti JL, Capozza RP, Cointry GR, Garcia SL, Plotkin H, Alvarez Figueira ML, Zanchetta JR: Gender-related differences in the relationship between densitometric values of whole-body bone mineral content and lean body mass in humans between 2 and 87 years of age. Bone 1998;22:683–690.
48.
Schiessl H, Frost HM, Jee WSS: Perspectives: Estrogen and bone-muscle strength and ‘mass’ relationships. Bone 1998;22:1–6.
49.
Schiessl H, Ferreti JL, Tysarczyk-Niemeyer G, Willnecker J, Wilhelm G: The role of muscles to the mechanical adaptation of bone; in Lyritis GP (ed): Advances in Osteoporosis, vol I. Athens, Hylonome Editions, 1998, pp 53–62.
50.
Schönau E (ed): Paediatric Osteology. New Trends and Diagnostic Possibilities. Amsterdam, Elsevier Science, 1996.
51.
Schönau E, Westermann F, Mokow E, Scheidhauer K, Werhahn E, Stabrey A, Müller-Berghaus J: The functional muscle–bone unit in health and disease; in Schönau E, Matkovic V (eds): Paediatric Osteology. Prevention of Osteoporosis – a Paediatric Task? Amsterdam, Excerpta Medica, 1998, pp 191–202.
52.
Schönau E, Frost HM: The ‘muscle strength–bone strength’ relationship in humans. A review. Proceedings of the Third International Congress on Osteoporosis, 31 March–3 April, 1999, Xi’an, China, 1999. Beijing, Chinese Osteoporosis Society, 1999, pp 84–89.
53.
Ferretti JL, Frost HM, Schiessl H: On new opportunities for absorptiometry. J Clin Densitom 1998;1:41–53.
54.
Schroll M, Petti E, Avlund K: Postural balance, its sensory-motor correlates and self-reported functional ability in 75-year old men and women: A cross-sectional comparative study; in Lyritis GP (ed): Musculoskeletal Interactions. Athens, Hylonome Editions, 1999, pp 53–66.
55.
Vanderschueren D, Bouillon R: Androgens and bone. Calcif Tissue Int 1995;56:341–346.
56.
Frost HM: Skeletal structural adaptations to mechanical usage (SATMU): 3. The hyaline cartilage modeling problem. Anat Rec 1990;226:423–432.
57.
Frost HM: Joint anatomy, design and arthroses: Insights of the Utah paradigm. Anat Rec 1999;55:162–174.
58.
Kippel JH, Dieppe PA (eds): Rheumatology. New York, Mosby-Year Book, Inc, 1994.
59.
Turner CH, Takano Y, Owan I: Aging changes mechanical loading thresholds for bone formation in rats. J Bone Miner Res 1995;10:1544–1549.
60.
Bergman RJ, Gazit D, Kahn AJ, Gruber H, McDougall S, Hahn TJ: Age-related changes in osteogenic stem cells in mice. J Bone Miner Res 1996;11:568–577.
61.
Ziegler BL, Valtieri M, Almeida Porada R, De Maria R, Muller R, Masella B, Gabianelli M, Casella I, Pelosi E, Bock T, Zanjani ED, Peschle C: KDR receptor: A key marker defining hematopoietic stem cells. Science 1999;285:1553–1558.
62.
Kannus P, Pakkari J, Koskinen S, Niemi S, Jarvinen M, Vuori I: Fall-induced injuries and deaths among older adults. JAMA 1999;281:1895–1899.
63.
Brown W, Haglund K: Landmarks. J NIH Res 1995;7:54–59.
64.
Recker RR (ed): Bone Histomorphometry. Techniques and Interpretation. Boca Raton, CRC Press, 1983.
65.
Parfitt AM: Problems in the application of in vitro systems to the study of human bone remodeling. Calcif Tissue Int 1995;56(suppl 1):S5–S7.
66.
Parfitt AM: Skeletal heterogeneity and the purposes of bone remodeling; in Marcus R, Feldman D, Kelsey J (eds): Osteoporosis. San Diego, Academic Press, 1996, pp 315–329.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.